Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlos Grande

Showing results (51-60 of 94) with videos related to

Pageof 10
Sort By:
Haematologica|June 12, 2013
First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO groupReyes Arranz, Ana García-Noblejas, Carlos Grande, et al.
Haematologica|February 11, 2010
Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study GroupAlbert Oriol, Susana Vives, Jesús-María Hernández-Rivas, et al.
Cardiology Journal|October 28, 2021
Time to -30°C as a predictor of acute success during cryoablation in patients with atrial fibrillationCarlos Antonio Álvarez-Ortega, Miguel Angel Ruiz, César Solórzano-Guillén, et al.
Haematologica|October 24, 2008
R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO studyAlejandro Martín, Eulogio Conde, Montserrat Arnan, et al.
Cancer|August 14, 2014
Prognostic significance of complex karyotype and monosomal karyotype in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocolsCristina Motlló, Josep-María Ribera, Mireia Morgades, et al.
Acta Haematologica|May 19, 2016
Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly PatientsEva González-Barca, Miguel A Canales, Antonio Salar, et al.
Plos One|March 11, 2025
Genetic subtyping by Whole Exome Sequencing across Diffuse Large B Cell Lymphoma and Plasmablastic LymphomaAitana Avendaño Pomares, Laura Rodríguez Merino, Sonia González, et al.
Cancer|January 31, 2013
Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab)Josep-Maria Ribera, Olga García, Carlos Grande, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2004
Influence of biologic markers on the outcome of Hodgkin's lymphoma: a study by the Spanish Hodgkin's Lymphoma Study GroupCarlos Montalbán, Juan F García, Víctor Abraira, et al.
Cancers|April 14, 2026
Integrated Single-Cell and Spatial Multi-Omics of Clonal Precursors and Immune Niches in Germinal Center LymphomasSofía Huerga-Domínguez, Beñat Ariceta, Paula Aguirre-Ruiz, et al.
Pageof 10

Showing results (51-60 of 94) with videos related to

Sort By:
Pageof 10
Haematologica|June 12, 2013
First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO groupReyes Arranz, Ana García-Noblejas, Carlos Grande, et al.
Haematologica|February 11, 2010
Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study GroupAlbert Oriol, Susana Vives, Jesús-María Hernández-Rivas, et al.
Cardiology Journal|October 28, 2021
Time to -30°C as a predictor of acute success during cryoablation in patients with atrial fibrillationCarlos Antonio Álvarez-Ortega, Miguel Angel Ruiz, César Solórzano-Guillén, et al.
Haematologica|October 24, 2008
R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO studyAlejandro Martín, Eulogio Conde, Montserrat Arnan, et al.
Cancer|August 14, 2014
Prognostic significance of complex karyotype and monosomal karyotype in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocolsCristina Motlló, Josep-María Ribera, Mireia Morgades, et al.
Acta Haematologica|May 19, 2016
Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly PatientsEva González-Barca, Miguel A Canales, Antonio Salar, et al.
Plos One|March 11, 2025
Genetic subtyping by Whole Exome Sequencing across Diffuse Large B Cell Lymphoma and Plasmablastic LymphomaAitana Avendaño Pomares, Laura Rodríguez Merino, Sonia González, et al.
Cancer|January 31, 2013
Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab)Josep-Maria Ribera, Olga García, Carlos Grande, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2004
Influence of biologic markers on the outcome of Hodgkin's lymphoma: a study by the Spanish Hodgkin's Lymphoma Study GroupCarlos Montalbán, Juan F García, Víctor Abraira, et al.
Cancers|April 14, 2026
Integrated Single-Cell and Spatial Multi-Omics of Clonal Precursors and Immune Niches in Germinal Center LymphomasSofía Huerga-Domínguez, Beñat Ariceta, Paula Aguirre-Ruiz, et al.
Pageof 10